Short on resources, L.A. County's public hospitals may soon ration care. 'Triage officers' will decide who gets treated and who is too sick to be saved.
ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury
Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases
Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia
A potentially modifying effect on the progression of the inflammatory cascade in sepsis
Pending positive data, the company aims to move into Phase 2b by end of 2021
Regulatory News:
ABIONYX Pharma (
FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that it has received authorization from the Italian authorities to launch a clinical trial named
Message :
Required fields
FDA’s decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded
VANCOUVER, Washington, Dec. 22, 2020 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company ), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a treating physician has received authorization from the U.S. Food and Drug Administration (“FDA”) to administer leronlimab for a COVID-19 patient under emergency IND (eIND).
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very thankful the FDA is allowing severe-to-critical COVID-19 patients access to Vyrologix™ (leronlimab) again under eIND while we await the unblinding of data from our recently completed Phase 3 registrational trial. We are receiving daily requests from families seeking o
FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn s Phase 3 Trial OTC Markets:CYDY globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.